{'fraction_non_alphanumeric': 0.023318385650224215, 'fraction_numerical': 0.0, 'mean_word_length': 5.564705882352941, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A review of the latest research medications and information on the inflammatory, molecular, pathological, and targeted aspects of breast cancer

Cancer is a complex illness involving a wide variety of genes and proteins regulated by various epigenetic and hereditary transcriptional alterations. Several molecular alterations characterize breast cancer (BC), one of the most lethal forms of female malignancy. As western lifestyles become more common, cities expand, and people live longer, BC’s prevalence and death rate continue to rise. Despite the availability of several cutting-edge methods for diagnosing and treating BC, it continues to be the leading cause of mortality among women. The clinical, pathological, and molecular aspects of BC are all highlighted in this overview. In addition, the involvement of risk factors, biomarkers, immunotherapy, and experimental medications through tumor targets and immune systems in the treatment of BC has been discussed. BC problems and future views also detail the many techniques for tumor targeting using nanocarriers, including clinical trials of these agents.